Holen Sie sich die Stockscreener-App
4.77
0.42%
-0.04
Schlusskurs vom Vortag:
$4.81
Offen:
$4.87
24-Stunden-Volumen:
23,977
Relative Volume:
0.16
Marktkapitalisierung:
$20.34M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-21.21M
KGV:
-0.1463
EPS:
-32.6
Netto-Cashflow:
$-16.86M
1W Leistung:
+10.11%
1M Leistung:
+7.64%
6M Leistung:
+0.63%
1J Leistung:
+18.41%
1-Tages-Spanne:
$4.77
$4.88
1-Wochen-Bereich:
$4.35
$5.00
52-Wochen-Spanne:
$1.8001
$20.83
Cingulate Inc Stock (CING) Company Profile
Firmenname
Cingulate Inc
Sektor
Branche
Telefon
(913) 942-2300
Adresse
1901 W. 47TH PLACE, KANSAS CITY
Vergleichen Sie CING mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CING
Cingulate Inc
|
4.79 | 18.81M | 0 | -21.21M | -16.86M | -32.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.71 | 123.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
546.35 | 60.43B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
321.75 | 42.07B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.58 | 34.47B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.75 | 27.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Cingulate Inc Stock (CING) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-10 | Eingeleitet | ROTH MKM | Buy |
| 2023-12-22 | Herabstufung | Laidlaw | Buy → Hold |
Cingulate Inc Aktie (CING) Neueste Nachrichten
What drives Cingulate Inc. Equity Warrant stock priceSuperior returns - Jammu Links News
Cingulate Inc. Stock Analysis and ForecastFree Market Volatility Navigation Tips - Jammu Links News
Cingulate Inc. Equity Warrant Stock Analysis and ForecastTremendous growth opportunities - Jammu Links News
What makes Cingulate Inc. Equity Warrant stock attractive to long term investors200 Percent Profit Outlook - newser.com
Why Cingulate Inc. stock attracts strong analyst attentionLow Risk ROI Maximization - newser.com
How Cingulate Inc. stock performs during market volatilityFree Market Analysis Group - Newser
Why Cingulate Inc. Equity Warrant stock attracts strong analyst attentionQuick Profit Idea Stream - Newser
What makes Cingulate Inc. Equity Warrant stock price move sharplyShort Term Risk Controlled Alerts - Newser
How Cingulate Inc. Equity Warrant stock performs during market volatilityFree Stock Index Interpretation - Newser
What makes Cingulate Inc. stock price move sharplyFree Stock Movement Tracking - Newser
Cingulate hires chief legal officer ahead of filing for FDA approval - The Business Journals
Cingulate appoints Nilay Patel as Chief Legal Officer - TipRanks
Cingulate names Nilay Patel as chief legal officer ahead of FDA filing By Investing.com - Investing.com South Africa
Cingulate Inc. Appoints Nilay Patel as Chief Legal Officer - MarketScreener
Cingulate names Nilay Patel as chief legal officer ahead of FDA filing - Investing.com
Cingulate Appoints Nilay Patel as Chief Legal Officer to Support Growth ahead of New Drug Application - GlobeNewswire
Cingulate Bolsters Executive Team With Key Legal Hire as ADHD Drug Heads to FDA Review - Stock Titan
Cingulate (NASDAQ:CING) Stock Price Up 3.3% – Here’s What Happened - Defense World
Stonegate Capital Partners Initiates Coverage on Cingulate Inc. (CING) - TradingView
Breakthrough Once-Daily ADHD Drug Targets $22B Market: Analyst Coverage Reveals Commercial Launch Plans - Stock Titan
Cingulate Inc. (NASDAQ:CING) Sees Large Increase in Short Interest - Defense World
Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets - mx.advfn.com
FDA and Cingulate Aligned with Filing Requirements for New Drug Application for Lead ADHD Asset CTx-1301 - mx.advfn.com
Cingulate Inc. expands equity plan following stockholder approval - Investing.com
Cingulate Inc Approves Key Proposals at Annual Meeting - TipRanks
Cingulate Inc. expands equity plan following stockholder approval By Investing.com - Investing.com India
Cingulate (NASDAQ:CING) Price Target Raised to $61.00 at Ascendiant Capital Markets - Defense World
Life365 Appoints Healthcare Veteran Jay Roberts as Chief Development Officer - Quantisnow
CING: Ascendiant Capital Raises Price Target to $61.00 | CING St - GuruFocus
Healthcare Tech Leader Life365 Taps Former Nasdaq CEO Jay Roberts to Drive AI-Powered Growth Strategy - Stock Titan
What is Roth Capital’s Estimate for Cingulate Q2 Earnings? - Defense World
McCann Joburg acquires a healthcare marketing company - Bizcommunity
Cingulate Reports Positive Data From Phase 3 Study Of CTx-1301 In Pediatric ADHD - Nasdaq
Cingulate announces efficacy results from Phase 3 study of CTx-1301 - TipRanks
Cingulate (CING) Reveals Promising Phase 3 Results for ADHD Treatment | CING Stock News - GuruFocus
Efficacy Results Announced from Cingulate’s Phase 3 Pediatric Study of CTx-1301 (dexmethylphenidate) for ADHD - GlobeNewswire
CING: Roth Capital Lowers Price Target, Maintains Buy Rating | CING Stock News - GuruFocus
CING: Roth Capital Adjusts Price Target Amidst CTx-1301 Developm - GuruFocus
Cingulate price target lowered to $11 from $12 at Roth Capital - TipRanks
CING: Roth Capital Adjusts Price Target Amidst CTx-1301 Developments | CING Stock News - GuruFocus
Cingulate Retail Buzz Rises After FDA Greenlights Summer NDA Filing For ADHD Drug - MSN
CING: First Quarter 2025 Results - Yahoo Finance
Cingulate receives FDA meeting feedback on ADHD drug By Investing.com - Investing.com Canada
Anchoring Your Portfolio: Is CING Stock a Safe Harbor? - investchronicle.com
Cingulate Retail Buzz Rises After FDA Greenlights Summer NDA Filing For ADHD Drug By Stocktwits - Investing.com India
Cingulate, Inc. Reports Increased Losses Amid R&D Expansion - TipRanks
Cingulate receives formal pre-NDA meeting minutes from FDA for CTx-1301 - TipRanks
Finanzdaten der Cingulate Inc-Aktie (CING)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.86%
0.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):